Pharma & Biotech
Outlook Therapeutics Insider Bets $5 Million as FDA Clears Path for Eye Drug
A director at Outlook Therapeutics has put more than $5 million of his own money on the line, scooping up...
Novo Nordisk Sharpens Its Pipeline Edge as Longevity Pivot Takes Shape
The Danish pharmaceutical heavyweight arrived at the American Diabetes Association congress in New Orleans armed with a double dose of...
Ocugen Faces a Moment of Truth as Clinical Catalysts Collide With a 55% Plunge
The divergence between Ocugen's scientific trajectory and its stock price has rarely been starker. The biotech's shares closed at €1.05...
Novo Nordisk’s Data Breach and Clinical Defeat Leave Investors with Little to Cheer
The Danish drugmaker entered the week with a promising oral medication and emerged facing a cybersecurity crisis and a clinical...
BioNTech Bets Big on Oncology as $1 Billion Buyback and First FDA Filing Converge
The Mainz-based biotech firm finds itself in an unusual position: burning through cash on R&D while sitting on a €16.8...
BioNTech at a Crossroads: FDA Filing Looms as Phase 3 Pipeline Takes Shape
The shares trade at €77 — roughly 27% below the 52-week high and below both their 50-day and 200-day moving...
Ocugen’s Mutation-Agnostic Gene Therapy Edges Toward FDA Filing as $130M Financing Secures Runway to 2028
Ocugen is betting that a single therapeutic can rewrite the rules for treating inherited retinal diseases. Its lead candidate, OCU400,...
Bayer’s Slow Build: Clinical Evidence and Margin Pressures Define the Next Chapter
Bayer is attempting to write a new chapter, one built on clinical proof rather than corporate promises. The German conglomerate's...
BioNTech’s Oncology Data Wows, but the Stock Won’t Budge: A $1 Billion Buyback Meets Investor Skepticism
The numbers from Chicago were impressive. On May 30, BioNTech and Bristol Myers Squibb unveiled interim Phase 2 results for...
Novo Nordisk’s 15 Billion Kroner Buyback Sends a Message, but the Market Isn’t Listening
The Danish drugmaker is buying back its own stock at a furious pace just as the shares slide toward a...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
